Breaking News Instant updates and real-time market news.

T

AT&T

$34.56

-0.08 (-0.23%)

, TWX

Time Warner

$89.76

2.05 (2.34%)

12:28
11/21/17
11/21
12:28
11/21/17
12:28

On The Fly: Top stock stories at midday

Stocks opened sharply higher and continued to tack on gains throughout the morning. In the process, the S&P crossed 2,600 for the first time and the Nasdaq hit a new all-time high. Meanwhile, oil prices are higher by 0.5% after struggling the past few sessions. ECONOMIC EVENTS: In the U.S., existing home sales grew 2.0% to a 5.48M unit rate in October, beating estimates. COMPANY NEWS: As widely anticipated, the U.S. Department of Justice confirmed last night that it is suing to block AT&T (T) and Time Warner's (TWX) merger deal. In response, AT&T's General Counsel said the lawsuit is "a radical and inexplicable departure from decades of antitrust precedent" and the company is "confident that the Court will reject the Government's claims" and permit the merger. Meanwhile, another U.S. regulator made its own proposal that could benefit AT&T, as FCC Chairman Ajit Pai formally proposed to end net neutrality rules put in place by the Obama administration. MAJOR MOVERS: Among the notable gainers following their earnings reports were Jacobs Engineering (JEC), which rose 9%, and Medtronic (MDT), which added 5%. Among the noteworthy losers following their earnings reports were Campbell Soup (CPB), which dropped 8%, DSW (DSW), which fell 13%, and Signet Jewelers (SIG), which fell 27%. Also lower was Cytokinetics (CYTK), which plunged 27% after the company announced that the Phase 3 tirasemtiv study in amyotrophic lateral sclerosis patients missed on both primary and secondary endpoints. INDEXES: Near midday, the Dow was up 176.15, or 0.75%, to 23,606.48, the Nasdaq was up 64.05, or 0.94%, to 6,854.77, and the S&P 500 was up 16.98, or 0.66%, to 2,599.12.

T

AT&T

$34.56

-0.08 (-0.23%)

TWX

Time Warner

$89.76

2.05 (2.34%)

JEC

Jacobs Engineering

$65.09

5.75 (9.69%)

MDT

Medtronic

$82.96

4.06 (5.15%)

CPB

Campbell Soup

$46.14

-3.79 (-7.59%)

DSW

DSW

$19.57

-2.96 (-13.14%)

SIG

Signet Jewelers

$55.48

-20.36 (-26.85%)

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 29

    Nov

  • 01

    Dec

  • 23

    Jan

  • 24

    Jan

T AT&T
$34.56

-0.08 (-0.23%)

11/21/17
CHLM
11/21/17
NO CHANGE
Target $114
CHLM
Buy
Dycom price target raised to $114 from $90 at Craig-Hallum
Craig-Hallum analyst Christian Schwab raised his price target for Dycom (DY) to $114 from $90 following quarterly results and as the worst of AT&T's (T) spending moderation seems behind it. The analyst reiterates a Buy rating on Dycom's shares.
11/21/17
NOMU
11/21/17
NO CHANGE
Target $42
NOMU
Buy
AT&T price target lowered to $42 from $45 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal lowered his price for AT&T (T) shares target to $42 after the Justice Department filed a lawsuit to block the company's acquisition of Time Warner (TWX). The analyst notes he didn't lowered his target post the Q3 video miss given the pending deal. He believes the shares have "room to run" with or without Time Warner and keeps a Buy rating on AT&T.
11/21/17
BARD
11/21/17
NO CHANGE
Target $42
BARD
Outperform
Merits of antitrust case favor AT&T, says Baird
Baird analyst William Power noted the DOJ sued to block the AT&T (T) and Time Warner (TWX) deal largely on the grounds that the merger would harm consumers due to higher content prices. The analyst finds it difficult to believe that, given other competition, the company would be able to significantly raise pricing for Turner properties or HBO and risk driving away current partners. He said although his thesis is at risk from the suit, he ultimately believes the merits of the case favor AT&T. Power reiterated his Outperform rating and $42 price target on AT&T shares.
11/21/17
DBAB
11/21/17
NO CHANGE
Target $37
DBAB
Hold
AT&T shares likely to remain range-bound, says Deutsche Bank
Deutsche Bank analyst Matthew Niknam expects shares of AT&T (T) to remain relatively range-bound in the near-term due to heightened regulatory risks around the company's proposed merger with Time Warner (TWX). The analyst notes that his standalone AT&T estimates continue to imply flattish earnings growth for Q4 and in upcoming years. He sees the Justice Department suit capping any near-term upside and trimmed his price target for Hold-rated AT&T to $37 from $38.
TWX Time Warner
$89.76

2.05 (2.34%)

11/21/17
WELS
11/21/17
NO CHANGE
Target $84
WELS
Market Perform
Time Warner price target lowered to $84 from $100 at Wells Fargo
Wells Fargo analyst Marci Ryvicker lowered her price target for Time Warner (TWX) to $84 from $100 to reflect standalone value, in light of the recent news that the DOJ will be suing to block the merger with AT&T (T). The analyst reiterates a Market Perform rating on Time Warner's shares.
JEC Jacobs Engineering
$65.09

5.75 (9.69%)

02/22/17
ARGS
02/22/17
NO CHANGE
ARGS
Jacobs Engineering recent weakness creates buying opportunity, says Argus
Argus analyst John Eade says that Jacobs' stock has underperformed for the past two months, falling 2%. He says that the company's turnaround is continuing to progress, while it should benefit from the increased focus on infrastructure. The analyst keeps a Buy rating on the shares.
08/17/17
ARGS
08/17/17
NO CHANGE
ARGS
Jacobs Engineering weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the underperformance by Jacobs over the past three months has created a buying opportunity. The analyst says that the company's performance is progressing, and he is upbeat about its turnaround strategy. Eade cut his price target on the shares to $62 from $72 and keeps a Buy rating on the stock.
08/03/17
SBSH
08/03/17
DOWNGRADE
Target $62
SBSH
Neutral
Jacobs Engineering downgraded to Neutral from Buy at Citi
Citi analyst Andrew Kaplowitz downgraded Jacobs Engineering to Neutral saying the price paid for CH2M is expensive and that the company's balance sheet is no longer a catalyst. The analyst lowered his price target for the shares to $62 from $66.
06/02/17
ARGS
06/02/17
NO CHANGE
ARGS
Jacobs Engineering weakness creates buying opportunity, says Argus
Argus analyst John Eade says that Jacobs is "showing signs of a turnaround" after the stock declined 3% over the last three months. He notes that the company reported better than expected Q2 results, and he thinks that it can benefit from infrastructure enhancement plans in the U.S., Canada, and Australia. The analyst recommends buying the shares.
MDT Medtronic
$82.96

4.06 (5.15%)

11/20/17
RHCO
11/20/17
NO CHANGE
Target $92
RHCO
Buy
Medtronic price target lowered to $92 from $96 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Medtronic to $92 and kept his Buy rating. Nudell is modelling Q2 hurricane impact of about $59M relative to $55M-$65M guidance along with a less favorable FX adjustment of negative $18M. The analyst says he will monitor for an update on any expected residual storm impact for the rest of the year as well as any color on the company's new product pipeline.
10/10/17
BMOC
10/10/17
NO CHANGE
Target $89
BMOC
Outperform
BMO sees $250M impact on Medtronic from hurricane manufacturing disruption
BMO Capital analyst Joanne Wuensch lowered her price target for Medtronic to $89 from $92, modeling a $250M impact on manufacturing in Puerto Rico resulting from Hurricane Maria. Wuensch notes that most of the impact will occur in Q2 of FY18, also lowering her EPS target for the year to $4.63 from $4.78. The analyst kept her Outperform rating on the stock.
10/10/17
NEED
10/10/17
NO CHANGE
Target $94
NEED
Buy
Medtronic shares remain attractive despite hurricane impact, says Needham
Needham analyst Mike Matson lowered his price target on Medtronic to $94 from $95 to account for about $250M estimated negative impact from Puerto Rico manufacturing disruption due to Hurricane Maria. However, the analyst views the impact as temporary, maintaining his Buy rating given the large discount in stock price that Matson sees relative to peers. He also notes that reports of the company's "product cycle demise have been greatly exaggerated" and remains confident that Medtronic can sustain a mid-single digit revenue growth rate.
10/16/17
SBSH
10/16/17
NO CHANGE
Target $359.33
SBSH
Buy
TransEnterix not 'in the same league' as Intuitive Surgical, says Citi
Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.
CPB Campbell Soup
$46.14

-3.79 (-7.59%)

09/01/17
DBAB
09/01/17
NO CHANGE
Target $51
DBAB
Hold
Campbell Soup price target lowered to $51 from $58 at Deutsche Bank
Deutsche Bank analyst Rob Dickerson lowered his price target for Campbell Soup to $51 saying management maintained a relatively cautious tone after missing Q4 consensus estimates. The analyst sees a "number of upcoming headwinds" for the company and notes its 2018 will largely be an investment year. He keeps a Hold rating on Campbell.
09/01/17
GSCO
09/01/17
NO CHANGE
Target $45
GSCO
Neutral
Campbell Soup price target lowered to $45 from $49 at Goldman Sachs
Goldman analyst Jason English lowered Campbell Soup's price target to $45 from $49 and maintained a Neutral rating citing disappointing results and eroding fundamentals. The analyst remains on the sidelines given relative under-performance versus peers and sees risk of multiple compression.
09/19/17
PIPR
09/19/17
DOWNGRADE
Target $72
PIPR
Neutral
Kellogg downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery downgraded Kellogg (K) to Neutral saying cereal could be at risk from shrinking center store space. Recent comments by Kroger (KR) and Campbell Soup (CPB) indicate retailer pushback is a real threat to packaged food suppliers, Lavery tells investors in a research note. He adds that scanner data suggests Kellogg's sales trends are worse than expected in both snacks and cereal. The analyst dropped his price target for Kellogg to $72 from $78.
09/06/17
FBCO
09/06/17
NO CHANGE
Target $43
FBCO
Underperform
Campbell Soup, Wal-Mart still negotiating, says Credit Suisse
Following up on Campbell Soup's (CPB) public disagreement in the soup category with Wal-Mart (WMT), Credit Suisse analyst Robert Moskow says the dispute specifically relates to Wal-Mart's demands for lower everyday price points on Campbell's condensed soup products. While this dispute does not appear to involve General Mills' (GIS) Progresso brand or the ready-to-serve category at this time, the analyst notes that Wal-Mart presumably could threaten to give more shelf space to General Mills or its Great Value brand at Campbell's expense. Campbell and Wal-Mart are still negotiating, Moskow points out, adding that it may be a good thing for the stock if Campbell can get Wal-Mart to agree to a compromise. The analyst reiterates an Underperform rating and $43 price target on Campbell's shares.
DSW DSW
$19.57

-2.96 (-13.14%)

11/16/17
11/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Outperform from Market Perform at BMO Capital with analyst Daniel Salmon saying that despite the lack of near-term catalysts, the market underappreciates longer-term factors. 2. Dollar General (DG) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying Dollar General's "long-term profit algorithm" will return in 2018. 3. RH (RH) upgraded to Buy from Neutral at Citi with analyst Geoffrey Small saying the company's initial outlook for 2018 alleviates concerns around the balance sheet and uncertainty regarding demand as the retailer backed off of elevated levels of sales and promotions. 4. Regions Financial (RF) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Ryan Nash saying he sees better than expected net interest margin, improving loan growth and increased capital returns helping Regions reach its efficiency goals in 2018. 5. DSW (DSW) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser citing momentum in the core women's business and well-controlled inventory levels, which suggest positive inflections are at hand. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/17
SUSQ
11/16/17
UPGRADE
SUSQ
Positive
DSW upgraded to Positive from Neutral at Susquehanna
11/02/17
11/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Square (SQ) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing valuation for the rating change and upped his price target for the shares to $36 from $29. 2. Papa John's (PZZA) downgraded to Neutral from Buy at BTIG with analyst Peter Saleh citing an uncertain sales outlook, increased competitive pressures, and modest earnings growth near-term. 3. Newell Brands (NWL) downgraded to Neutral from Overweight at JPMorgan with analyst Andrea Teixeira citing the company's third quarter miss and lowered fiscal 2017 guidance. This marks the second time in two months Newell lowered its outlook, Teixeira tells investors in a post-earnings research note. 4. Oclaro (OCLR) downgraded to Buy from Strong Buy at Needham and to Hold from Buy at Craig-Hallum. 5. DSW (DSW) downgraded to Neutral from Buy at B. Riley FBR with analyst Jeff Van Sinderen saying the multi-year fashion shift away from boots is intensifying, and is being made worse by warmer weather. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/17
SUSQ
11/16/17
UPGRADE
Target $23
SUSQ
Positive
DSW upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded DSW to Positive from Neutral. The analyst cited momentum in the core women's business and well-controlled inventory levels, which suggest positive inflections are at hand. He believes the implementation and integration of company-wide planning systems and tools will lead to improved results. Poser raised his price target to $23 from $21 on DSW shares.
SIG Signet Jewelers
$55.48

-20.36 (-26.85%)

11/14/17
BUCK
11/14/17
NO CHANGE
Target $72
BUCK
Neutral
Signet Jewelers price target raised to $72 from $55 at Buckingham
Buckingham analyst Scott Krasik raised his price target on Signet Jewelers shares to $72 from $55 citing his more favorable view of management and new CEO Virginia Drosos, easier comparisons this holiday and the stabilization of jewelry industry sales. He keeps a Neutral rating on the stock, but said he would look to take a more positive view once there is some visibility on the company being able to pull back on promotions and a line of sight to the resolution of the next phase of its credit review process.
11/21/17
JPMS
11/21/17
NO CHANGE
JPMS
Pandora A/S selloff on Signet results overdone, says JPMorgan
JPMorgan analyst Chiara Battistini views the selloff today in shares of Pandora A/S (PANDY) following Signet Jewelers' (SIG) Q3 results as overdone. The analyst believes company-specific issues drove Signet's guidance cut and does not see any read-through to Pandora.
11/02/17
SUSQ
11/02/17
INITIATION
Target $60
SUSQ
Neutral
Signet Jewelers initiated with a Neutral at Susquehanna
Susquehanna analyst Bill Dreher initiated Signet Jewelers with a Neutral rating as he remains cautious following its recent results, which have been challenged and choppy. Dreher has a $60 price target on Signet Jewelers shares.
11/02/17
11/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tabula Rasa HealthCare (TRHC) initiated with an Overweight at First Analysis. 2. HollyFrontier (HFC) reinstated with an Overweight at Barclays. 3. Medidata (MDSO) initiated with a Neutral at Dougherty. 4. Tiffany (TIF) and Signet Jewelers (SIG) were initiated with a Neutral at Susquehanna, while Tapestry (TPR) and Michael Kors (KORS) were initiated with a Positive. 5. Prometic Life Sciences (PFSCF) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CYTK Cytokinetics
$11.10

-0.7 (-5.93%)

11/21/17
HCWC
11/21/17
NO CHANGE
Target $17
HCWC
Buy
Cytokinetics price target lowered to $17 from $26 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Cytokinetics to $17 after the company announced that the Phase 3 tirasemtiv study in amyotrophic lateral sclerosis patients missed on both primary and secondary endpoints. The analyst, however, believes the shares are undervalued on omecamtiv alone. He keeps a Buy rating on Cytokinetics.
10/06/17
GHSC
10/06/17
INITIATION
Target $24
GHSC
Buy
Cytokinetics initiated with a Buy at Seaport Global
Seaport Global analyst Vernon Bernardino initiated Cytokinetics with a Buy and $24 price target. The analyst is looking for news flow to be generated by the Tirasemtiv and CK-107 programs and their potential for positive results to drive upside.
05/08/17
JMPS
05/08/17
NO CHANGE
JMPS
Cytokinetics has positive read through from Radicava, says JMP Securities
JMP Securities analyst Jason Butler says that the approval of Radicava for ALS bodes well for Cytokinetics' ALS treatment, tirasemtiv, assuming that the latter drug shows positive results in an ongoing Phase 3 trial. The analyst thinks that .Radicava "can enhance the commercial prospects for tirasemtiv without representing direct competition." He keeps a $17 price target and an Outperform rating on the shares.
03/08/17
03/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Skyworks (SWKS) initiated at Wells Fargo. 2. Jagged Peak Energy (JAG) initiated with a Sector Perform at Scotia Howard Weil. 3. Splunk (SPLK) initiated with a Buy at Rosenblatt. 4. Laureate Education (LAUR) initiated with an Overweight at JPMorgan. 5. Cytokinetics (CYTK) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$187.86

2.13 (1.15%)

13:38
12/14/17
12/14
13:38
12/14/17
13:38
Hot Stocks
Netflix says FCC decision on net neutrality 'beginning of longer legal battle' »

Netflix tweeted from its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$117.84

0.4475 (0.38%)

13:34
12/14/17
12/14
13:34
12/14/17
13:34
Hot Stocks
EDF Renewable, Kimberly-Clark announce commercial operation at Rock Falls »

EDF Renewable Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKGAY

Merck KGaA

13:28
12/14/17
12/14
13:28
12/14/17
13:28
Periodicals
Merck KGaA revives efforts to enter U.S. MS pill market, Reuters reports »

Merck KGaA is reviving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$84.14

-1.88 (-2.19%)

, MKGAY

Merck KGaA

13:27
12/14/17
12/14
13:27
12/14/17
13:27
Periodicals
Perrigo prepping bid for Merck KGaA's consumer health division, Reuters reports »

Perrigo (PRGO) is…

PRGO

Perrigo

$84.14

-1.88 (-2.19%)

MKGAY

Merck KGaA

NSRGY

Nestle

$86.67

0.61 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDE

Coeur Mining

$7.37

-0.01 (-0.14%)

13:25
12/14/17
12/14
13:25
12/14/17
13:25
Conference/Events
Coeur Mining to host business news update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

13:20
12/14/17
12/14
13:20
12/14/17
13:20
General news
U.S. equities sank back into the red »

U.S. equities sank back…

EE

El Paso Electric

$58.63

0.21 (0.36%)

13:17
12/14/17
12/14
13:17
12/14/17
13:17
Hot Stocks
El Paso Electric says Texas commission approves rate increase »

El Paso Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
12/14/17
12/14
13:17
12/14/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
12/14/17
12/14
13:16
12/14/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
12/14/17
12/14
13:15
12/14/17
13:15
General news
Treasury Action: yields have drifted lower from early highs »

Treasury Action: yields…

EPE

EP Energy

$1.66

-0.115 (-6.50%)

, CRZO

Carrizo Oil & Gas

$19.55

-1.03 (-5.00%)

13:13
12/14/17
12/14
13:13
12/14/17
13:13
Hot Stocks
EP Energy reports deal with Carrizo Oil to buy certain properties in Eagle Ford »

EP Energy Corporation…

EPE

EP Energy

$1.66

-0.115 (-6.50%)

CRZO

Carrizo Oil & Gas

$19.55

-1.03 (-5.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

BGCP

BGC Partners

$15.79

-0.61 (-3.72%)

13:13
12/14/17
12/14
13:13
12/14/17
13:13
Hot Stocks
BGC Partners sees Newmark IPO price at $14-$15 per share »

BGC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

T

AT&T

$37.97

-0.07 (-0.18%)

, CHTR

Charter

$329.00

-0.99 (-0.30%)

13:12
12/14/17
12/14
13:12
12/14/17
13:12
Hot Stocks
FCC repeals net neutrality in 3-2 vote along party lines »

This afternoon, after…

T

AT&T

$37.97

-0.07 (-0.18%)

CHTR

Charter

$329.00

-0.99 (-0.30%)

CMCSA

Comcast

$38.58

-0.93 (-2.35%)

CMCSK

Comcast

VZ

Verizon

$52.53

-0.365 (-0.69%)

NFLX

Netflix

$187.86

2.13 (1.15%)

GOOG

Alphabet

$1,040.61

0.13 (0.01%)

GOOGL

Alphabet Class A

$1,051.39

2.62 (0.25%)

AMZN

Amazon.com

$1,164.13

-0.95 (-0.08%)

FB

Facebook

$178.30

1.34 (0.76%)

TWTR

Twitter

$22.54

0.875 (4.04%)

DISH

Dish

$48.99

-0.64 (-1.29%)

SNE

Sony

$44.60

-0.055 (-0.12%)

ETSY

Etsy

$20.16

-0.05 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 07

    Feb

  • 18

    Mar

MAC

Macerich

$66.99

0.22 (0.33%)

13:10
12/14/17
12/14
13:10
12/14/17
13:10
Options
Notable call spreads in Macerich March options »

Notable call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:10
12/14/17
12/14
13:10
12/14/17
13:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

TWTR

Twitter

$22.68

1.02 (4.71%)

12:57
12/14/17
12/14
12:57
12/14/17
12:57
Technical Analysis
Technical View: Twitter ticks new 52-week high, nearing breakout »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 07

    Feb

ORCL

Oracle

$50.20

0.145 (0.29%)

, ADBE

Adobe

$176.83

4.29 (2.49%)

12:55
12/14/17
12/14
12:55
12/14/17
12:55
Earnings
Notable companies reporting after market close »

Notable companies…

ORCL

Oracle

$50.20

0.145 (0.29%)

ADBE

Adobe

$176.83

4.29 (2.49%)

COST

Costco

$188.28

-0.02 (-0.01%)

JBL

Jabil Circuit

$27.90

-0.635 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

  • 09

    Jan

12:55
12/14/17
12/14
12:55
12/14/17
12:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD turned…

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.69

-0.06 (-0.02%)

12:50
12/14/17
12/14
12:50
12/14/17
12:50
Periodicals
House Speaker Ryan considers retirement in 2018, Politico says »

U.S. House Speaker Paul…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.69

-0.06 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$5.15

0.14 (2.79%)

12:50
12/14/17
12/14
12:50
12/14/17
12:50
Options
Far upside call buying in 3X leveraged bearish biotech fund »

Far upside call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNT

Cleantech Solutions

$5.81

0.2 (3.57%)

, BITCOIN

Bitcoin

12:49
12/14/17
12/14
12:49
12/14/17
12:49
Hot Stocks
Cleantech jumps as September news generates crypto buzz »

Shares of Cleantech…

CLNT

Cleantech Solutions

$5.81

0.2 (3.57%)

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

MPAD

Micropac Ind

12:41
12/14/17
12/14
12:41
12/14/17
12:41
Hot Stocks
Micropac approves special 10c per share dividend »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$85.88

0.275 (0.32%)

12:40
12/14/17
12/14
12:40
12/14/17
12:40
Options
Bullish play opened in Lowes »

Bullish play opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$85.42

-0.605 (-0.70%)

, MKGAY

Merck KGaA

12:36
12/14/17
12/14
12:36
12/14/17
12:36
Periodicals
Breaking Periodicals news story on Perrigo, Merck KGaA »

Perrigo prepping bid for…

PRGO

Perrigo

$85.42

-0.605 (-0.70%)

MKGAY

Merck KGaA

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$87.01

-0.88 (-1.00%)

12:32
12/14/17
12/14
12:32
12/14/17
12:32
Hot Stocks
Eli Lilly announces non-exclusive agreement with Rimidi for diabetes partnership »

Rimidi, a digital health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 31

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.